Erica Fidone, MD
Interventional Cardiology · Nacogdoches, TXNPI 1780095224
Payments from drug & device makers
Across 239 payments — averaging $53.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Asahi Intecc USA, Inc.$3K
- Philips North America LLC$3K
- Medtronic$2K
- Inari Medical, Inc.$605
- Angiodynamics, Inc.$529
- Stryker$468
- plus $4K from 28 others
What the payments were for
- Consulting fees$1,74014%
- Speaking & faculty fees$2,85622%
- Travel & lodging$1,51212%
- Food & beverage$6,60152%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Asahi Intecc USA, Inc. | 4 | $2,945 |
| Philips North America LLC | 23 | $2,909 |
| Medtronic(2 entities) | 27 | $1,553 |
| Inari Medical, Inc. | 17 | $605 |
| Angiodynamics, Inc. | 5 | $529 |
| Stryker | 9 | $468 |
| Novartis | 35 | $449 |
| Abbott | 15 | $439 |
| Boehringer Ingelheim | 11 | $413 |
| Boston Scientific | 11 | $359 |
| Amgen | 14 | $352 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $340 |
| Johnson & Johnson | 10 | $207 |
| Verge Medical, Inc. | 2 | $168 |
| Pfizer | 6 | $149 |
| Biotronik Inc. | 1 | $111 |
| Cordis US CORP. | 1 | $106 |
| E.r. Squibb & Sons, L.L.C. | 5 | $88 |
| Abiomed | 2 | $76 |
| Novo Nordisk | 3 | $55 |
| AstraZeneca | 3 | $49 |
| Cardiva Medical, Inc. | 2 | $43 |
| Shockwave Medical, Inc | 2 | $42 |
| Irhythm Technologies, Inc. | 2 | $40 |
| Amarin Pharma, Inc. | 1 | $33 |
| CMS Imaging, Inc. | 1 | $30 |
| Terumo Medical Corporation | 1 | $27 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $23 |
| Penumbra, Inc. | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Surmodics, Inc. | 1 | $17 |
| Cardiovascular Systems Inc. | 1 | $13 |
| Impulse Dynamics (USA) Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Asahi Peripheral Vascular Wires$2,507
- (9520) IGT Devices Undivided$1,270
- HawkOne$611
- (6554) Periph Vasc Undiv$600
- (6554) Peripheral Vascular Undivided$470
- PERIPHERAL VASCULAR$400
- TurboHawk$293
- AlphaVac$243
- JARDIANCE$233
- Auryon Laser System 100-120 Vac$176
- AVEIR$161
- FLASH Ostial System$111
- CT THROMBECTOMY SYSTEM KIT$111
- FLOWTRIEVER CATHETER, S$111
- Orsiro Mission$111
- CoreValve Evolut$110
- RADIAL 360$106
- Repatha$105
How this compares
$12,709 in reported general payments places this provider in the 55th percentile of 686 interventional cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 70 | $73,194 |
| EliquisApixaban | 74 | $65,228 |
| Repatha SureclickEvolocumab | 89 | $58,468 |
| EntrestoSacubitril/Valsartan | 22 | $22,849 |
| JardianceEmpagliflozin | 23 | $20,201 |
| Repatha PushtronexEvolocumab | 19 | $11,797 |
| Rosuvastatin Calcium | 151 | $1,775 |
| ClopidogrelClopidogrel Bisulfate | 146 | $1,717 |
| Metoprolol Succinate | 135 | $1,713 |
| Amiodarone Hcl | 19 | $1,645 |
| Olmesartan Medoxomil | 104 | $1,110 |
| Chlorthalidone | 76 | $1,092 |
| Losartan Potassium | 102 | $841 |
| Nifedipine ErNifedipine | 48 | $764 |
| Labetalol Hcl | 48 | $739 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $207 | $73,19470 claims |
| PfizerEliquis | $149 | $65,22874 claims |
| NovartisEntresto | $449 | $22,84922 claims |
| Boehringer IngelheimJardiance | $413 | $20,20123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 686 interventional cardiology providers in Texas.
Other interventional cardiology in Nacogdoches
- Robert StolerDallas$8.2M
- James ChoiDallas$5.2M
- Srinivasa PotluriPlano$5.1M
- Neal KleimanHouston$4.8M
- Juan GranadaHouston$4.3M
- Ira LieberKingwood$3.3M
- Cara Ann EastDallas$3M
- Abhijeet DhobleHouston$2.7M
- Jeffrey CarrTyler$2.7M
- M Asad KarimMcKinney$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.